Metabolic responses to the occurrence and chemotherapy of pancreatic cancer: biomarker identification and prognosis prediction

Tianhong Teng,Han Shi,Yanying Fan,Pengfei Guo,Jin Zhang,Xinyu Qiu,Jianghua Feng,Heguang Huang
DOI: https://doi.org/10.1038/s41598-024-56737-4
IF: 4.6
2024-03-25
Scientific Reports
Abstract:As the most malignant tumor, the prognosis of pancreatic cancer is not ideal even in the small number of patients who can undergo radical surgery. As a highly heterogeneous tumor, chemotherapy resistance is a major factor leading to decreased efficacy and postoperative recurrence of pancreatic cancer. In this study, nuclear magnetic resonance (NMR)-based metabolomics was applied to identify serum metabolic characteristics of pancreatic ductal adenocarcinoma (PDAC) and screen the potential biomarkers for its diagnosis. Metabolic changes of patients with different CA19-9 levels during postoperative chemotherapy were also monitored and compared to identify the differential metabolites that may affect the efficacy of chemotherapy. Finally, 19 potential serum biomarkers were screened to serve the diagnosis of PDAC, and significant metabolic differences between the two CA19-9 stratifications of PDAC were involved in energy metabolism, lipid metabolism, amino acid metabolism, and citric acid metabolism. Enrichment analysis of metabolic pathways revealed six shared pathways by PDAC and chemotherapy such as alanine, aspartate and glutamate metabolism, arginine biosynthesis, glutamine and glutamate metabolism, citrate cycle, pyruvate metabolism, and glycogolysis/gluconeogeneis. The similarity between the metabolic characteristics of PDAC and the metabolic responses to chemotherapy provided a reference for clinical prediction of benefits of postoperative chemotherapy in PDAC patients.
multidisciplinary sciences
What problem does this paper attempt to address?
### Problems the paper attempts to solve This paper aims to study the occurrence of pancreatic cancer (especially pancreatic ductal adenocarcinoma, PDAC) and the metabolic changes during chemotherapy by metabolomics methods, in order to identify potential diagnostic biomarkers and predict the effect of postoperative chemotherapy. Specifically, the paper mainly focuses on the following aspects: 1. **Screening of diagnostic markers**: - Use nuclear magnetic resonance (NMR) technology to analyze the serum metabolic characteristics of pancreatic cancer patients and healthy control groups, and screen out differential metabolites with potential diagnostic value. - The study found 19 potential serum biomarkers. These biomarkers are significantly different between PDAC patients and healthy control groups, involving multiple pathways such as energy metabolism, lipid metabolism, amino acid metabolism and citrate metabolism. 2. **Evaluation of chemotherapy effect**: - Monitor the metabolic changes of pancreatic cancer patients with different CA19 - 9 levels during postoperative chemotherapy, and identify differential metabolites that affect the chemotherapy effect. - By comparing the metabolites in the CA19 - 9 elevation group and the normal group, 14 significantly changed serum metabolites were found, and these metabolites may be related to the chemotherapy effect. 3. **Analysis of metabolic pathways**: - Perform metabolic pathway enrichment analysis on the screened differential metabolites, and determine six common metabolic pathways. These pathways are affected during the occurrence of PDAC and chemotherapy. - These pathways include alanine, aspartate and glutamate metabolism, arginine biosynthesis, glutamine and glutamate metabolism, citric acid cycle, pyruvate metabolism, and glycolysis/gluconeogenesis. ### Main findings - **Energy metabolism**: - The Warburg effect shows that normal cells mainly rely on mitochondrial oxidative phosphorylation for energy supply, while most cancer cells still prefer aerobic glycolysis even when the oxygen supply is sufficient. This leads to changes in the levels of glucose, lactate and pyruvate in the serum of PDAC patients. - The study found that the lactate levels in the PDAC group and the CA19 - 9 elevation group were significantly higher than those in the control group. As a product of aerobic glycolysis in cells, lactate can stimulate angiogenesis in the tumor microenvironment through vascular endothelial growth factor, promoting the invasion and metastasis of tumor cells. - **Lipid metabolism**: - Lipids provide energy for the proliferation of tumor cells and raw materials for membrane synthesis. The study found that the lipid metabolism in PDAC patients and chemotherapy groups has changed, and the serum lipoprotein level is also related to pancreatic cancer. - The changes in low - density lipoprotein (LDL) and very - low - density lipoprotein (VLDL) may be related to the activation of the ERK1/2 signaling pathway, thereby promoting the progression of PDAC and chemotherapy resistance. - **Amino acid metabolism**: - The study found that the levels of branched - chain amino acids (BCAA), glutamine, arginine and other amino acids in PDAC patients and during chemotherapy have changed, suggesting that amino acid metabolism remodeling plays an important role in the proliferation process of PDAC. - Glutamine becomes an important energy source through Kras - and MYC - induced metabolic reprogramming in tumor cells, participates in the citric acid cycle, and provides energy and carbon and nitrogen required for biosynthesis for tumor cells. ### Conclusion This study successfully identified potential diagnostic biomarkers of PDAC by metabolomics methods and revealed the metabolic changes that affect the curative effect during chemotherapy. These findings not only help to improve the early diagnosis rate of pancreatic cancer, but also provide a new perspective for predicting the effect of postoperative chemotherapy and a reference for clinical treatment.